In CAD, P2Y12 inhibitor vs. aspirin monotherapy reduces a composite CV outcome without increasing major bleeding.
Where this comes from
- Record sourced from PubMed, PMID 37931259.
- Also identified by DOI 10.7326/J23-0090.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Gragnano F, Cao D, Pirondini L, et al; PANTHER Collaboration. <b>P2Y<sub>12</sub> inhibitor or aspirin monotherapy for secondary prevention of coronary events.</b> J Am Coll Cardiol. 2023;82:89-105. 37407118.
Medical subject headings
- Aspirin
- Percutaneous Coronary Intervention